Tetanus booster

PreclinicalBiologic

WWashington University School of Medicine

Tetanus booster is one of 4 biologic programs targeting Diffuse Midline Glioma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diffuse Midline GliomaSuspended

Diffuse Midline GliomaPreclinical

Suspended

Competition

Competitive Landscape

4 competitors in Diffuse Midline Glioma

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Preclinical

1 2

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 3

PEP-CMV Vaccine

WWashington University School of Medicine

Preclinical

1 4

Tetanus booster

WWashington University School of Medicine

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diffuse Midline Glioma1 trial

Phase 1/2 Trial of PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma (PRiME II)

Suspended·WWashington University School of Medicine·Preclinical·NCT06639607·68 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tetanus booster. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tetanus booster compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tetanus booster. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Washington University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: WWashington University School of Medicine

Tetanus booster

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diffuse Midline Glioma1 trial

References

Drug Info

Quick Facts

Related News